News Exclusive GP leaders advise practices not to prescribe cholesterol lowering drug inclisiran BMJ 2023; 382 doi: https://doi.org/10.1136/bmj.p1757 (Published 01 August 2023) Cite this as: BMJ 2023;382:p1757 Article Related content Metrics Responses Peer review Related articles Practice PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations Published: 04 May 2022; BMJ 377 doi:10.1136/bmj-2021-069066 See more Why are UK cardiovascular deaths in under 65s rising again? BMJ May 19, 2025, 389 r1015; DOI: https://doi.org/10.1136/bmj.r1015 Prescribing parkrun: medicalising a walk in the park BMJ April 08, 2025, 389 r670; DOI: https://doi.org/10.1136/bmj.r670 GPs can prescribe tirzepatide to priority patient groups from June BMJ April 02, 2025, 389 r665; DOI: https://doi.org/10.1136/bmj.r665 Exercise referral rates for patients with risk of cardiovascular disease vary widely across England, study reports BMJ February 12, 2025, 388 r287; DOI: https://doi.org/10.1136/bmj.r287 Cardiovascular disease: Just one in 12 eligible people had health check last year, watchdog finds BMJ November 13, 2024, 387 q2518; DOI: https://doi.org/10.1136/bmj.q2518
